Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The pharmaceutical company's market cap has surpassed Tesla's, thanks to the rapid growth of its GLP-1 business.

Why Eli Lilly Deserves to Unseat Tesla Among the Magnificent 7

Pharma giant Eli Lilly and Co said expects revenues to grow by 18% in 2024 to more than $40 billion with the surge is attributed to the growing demand for its diabetes and obesity treatments, Mounjaro and Zepbound. The latter, an injectable weight-loss drug, achieved $175.8 million in global sales in the last quarter after receiving FDA approval in November.

Eli Lilly buoyed by demand for new weight loss drug

Eli Lilly (LLY) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.09 per share a year ago.

Eli Lilly (LLY) Tops Q4 Earnings and Revenue Estimates

Eli Lilly shares jumped in premarket Tuesday after the company reported better-than-expected fourth quarter results and revised its 2024 forecast ahead of expectations, amid soaring demand for its diabetes drug Mounjaro and newly-approved weight loss drug Zepbound.

Zepbound Maker Eli Lilly Forecasts Strong Profits Amid Rollout Of Weight Loss Drug

Eli Lilly Scored a strong Q4 win and provided healthy guidance Tuesday. Shares moved toward a profit-taking zone following a January breakout.

Eli Lilly Stock Veers Higher On Fourth-Quarter Beat

Shares of Eli Lilly and Co. LLY, +5.77% rallied toward a fifth-straight record close in premarket trading Tuesday, after the drug maker's fourth-quarter earnings beat expectations, helped by a 16% jump in prices, and provided an upbeat 2024 revenue outlook. Net income rose to $2.19 billion, or $2.42 a share, from $1.94 billion, or $2.14 a share, in the year-ago period.

Eli Lilly's stock surges toward a 5th straight record after an earnings beat and upbeat outlook

Eli Lilly & Co (NYSE: LLY) is trading up in premarket on Tuesday after coming in ahead of Street estimates in its fiscal fourth quarter on a solid launch of Zepbound (weight-loss drug) and higher prices for Mounjaro (diabetes drugs). Investors are pleased also because the management issued upbeat guidance for the future.

Eli Lilly beats Q4 estimates on solid demand for weight-loss drug

The quarterly results are the first to include sales of Eli Lilly's new weight loss drug Zepbound, which won FDA approval in early November.

Eli Lilly results blow past estimates on strong Zepbound launch, higher Mounjaro prices

Eli Lilly forecast 2024 profit above Wall Street estimates on Tuesday, driven by demand for its recently approved weight-loss drug Zepbound and diabetes medicine Mounjaro, both known chemically as tirzepatide.

Lilly sees 2024 profit above estimates on strong demand for weight-loss drug

Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound.

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance

DraftKings

Shopify

When finding stocks to own, growth stocks are a top priority. For those looking to invest with a truly long-term investing time horizon, growth stocks tend to outperform.

3 High-Octane Growth Stocks Not Slowing Down Any Time Soon

AstraZeneca

Artificial intelligence grabbed most of the headlines last year, but weight loss stocks were equally noteworthy. It grew slowly for several years but really went stratospheric last year.

NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?

Amgen

Amgen stock slumped Monday — as Eli Lilly stock hit a record high — after the company unveiled preclinical results for its weight-loss drug.

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record

Nowadays, the market sends mixed signals to virtually every investor attempting to participate today, squeezing out a few percentage points of gains from the stock movements. With the Federal Reserve (Fed) proposing interest rate cuts this year and a FedWatch tool at the CME Group NYSE: CME now pushing the probability of them happening by May of this year, there are a lot of itchy fingers today.

Markets suddenly price Eli Lilly stock for a breakout on earnings

The U.S. Food and Drug Administration's website said some doses of Eli Lilly's diabetes drug Mounjaro are available only in limited quantities through early March 2024.

FDA website shows limited availability of some doses of Lilly's Mounjaro

Eli Lilly is a leader in one of the fastest-growing pharmaceutical segments today: the weight-loss market. The company recently released a new treatment specifically approved for weight management.

After a 90% Gain, Is It Too Late to Buy Eli Lilly?

BioNTech SE

Merck

The pharma industry has developed some real blockbusters between novel vaccines and weight loss drugs over the past few years. This has increasingly led investors to view pharma stocks as a promising growth industry after years of underperformance, but many are top pharma stocks to sell.

3 Pharma Stocks to Sell in February Before They Crash and Burn

AbbVie

Novo Nordisk

Novartis

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.

4 Large Drug Stocks Trying to Survive the Industry Challenges

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Lilly (LLY), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Lilly (LLY) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

I forecast GLP-1 drugs to become the largest-selling pharmaceutical class, with US sales of $150 billion in 2030. GLP-1 agonists have shown favorable cardiovascular outcomes and beneficial effects on various organs, and in 2024 there will be data on Lilly's tirzepatide in NASH, sleep apnea and cardiovascular disease. Eli Lilly's upcoming earnings report and 2024 guidance, on February 6, will focus on Mounjaro and ZepBound, with potential for upward revenue revisions and stock performance.

Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value

Jazz Pharmaceuticals

There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024

Makers of Wegovy, Ozempic and Zepbound can't keep up with skyrocketing demand for their GLP-1 drugs, so insurance coverage isn't important for near-term growth.

Why Obesity Drug Coverage Doesn't Matter (Yet) for Lilly and Novo

Norway's giant wealth fund says Novo Nordisk and Eli Lilly could be on course to become the first health care companies to join the trillion-dollar club.

Norway's giant wealth fund touts possibility of Novo Nordisk, Eli Lilly joining the trillion-dollar club

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

News for Eli Lilly Stock (LLY)